CLOs on the Move


 
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.grail.com
  • 1525 O`Brien Drive
    Menlo Park, CA USA 94025
  • Phone: 650.542.0372

Executives

Name Title Contact Details
James Langston
Director, Corporate Legal Profile
Raakhee Kumar
Associate General Counsel Profile
Marissa Song
General Counsel and Corporate Secretary Profile

Similar Companies

Cornerstone BioPharma

At Cornerstone BioPharma, we are constantly striving to make good medicines better. We know that Healthcare providers and patients are concerned about the safety of today's medications-that makes tried and true medications very appealing. However, due to

maryville academy

maryville academy is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Tenaya Therapeutics

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.